Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EQUIFAX INCEFX · Entity 3235 | Director · CEO | July 24, 2026 | July 28, 2026 |
| FAIR ISAAC CORPFICO · Entity 3206 | Director | March 21, 2018 | March 22, 2018 |
| GENERAL ELECTRIC COGE · Entity 2813 | Senior Vice President | February 22, 2006 | February 24, 2006 |
| NCR Voyix CorpNCR · Entity 293 | Director | September 29, 2023 | October 03, 2023 |
| RAYMOND JAMES FINANCIAL INCRJF · Entity 3126 | Director | February 19, 2026 | February 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EQUIFAX INC
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 271,890 |
Last balance in matching sequence
After 2026-07-24 transaction · row 9
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
9 source rowsRow 1 · 2026-07-24 · Exercise / conversion · Acquired 37,791 · Balance 309,681 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 2 · 2026-07-24 · Sale · Disposed 500 · Balance 309,181 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F3: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 3 · 2026-07-24 · Sale · Disposed 600 · Balance 308,581 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F4: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 4 · 2026-07-24 · Sale · Disposed 600 · Balance 307,981 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F5: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 5 · 2026-07-24 · Sale · Disposed 1,300 · Balance 306,681 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F6: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 6 · 2026-07-24 · Sale · Disposed 2,936 · Balance 303,745 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F7: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 7 · 2026-07-24 · Sale · Disposed 4,112 · Balance 299,633 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F8: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 8 · 2026-07-24 · Sale · Disposed 6,200 · Balance 293,433 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F9: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 9 · 2026-07-24 · Sale · Disposed 21,543 · Balance 271,890 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F10: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. |
| Stock Option/Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $112.46 · Expires 2028-05-04 | Direct | 37,792 |
Reported balance
After 2026-07-24 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-07-24 · Exercise / conversion · Disposed 37,791 · Balance 37,792 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F11: The option vested in three equal annual increments beginning 5/4/2019. |
| Common StockSEC Table I · non-derivative | Indirect2-yr Apr 2025 GRAT | 2,350 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 2,350 |
| Common StockSEC Table I · non-derivative | Indirect2-yr Dec 2025 GRAT | 21,284 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 21,284 |
| Common StockSEC Table I · non-derivative | Indirect2-yr Jun 2025 GRAT | 38,332 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 38,332 |
| Common StockSEC Table I · non-derivative | Indirect2-yr May 2025 GRAT | 2,018 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 2,018 |
| Common StockSEC Table I · non-derivative | Indirect2-yr May 2026 GRAT | 18,562 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 18,562 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.
F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.
F3: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F4: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F5: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F6: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F7: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F8: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F9: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F10: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F11: The option vested in three equal annual increments beginning 5/4/2019.
FAIR ISAAC CORP
Report date March 21, 2018 · Filed March 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,174 |
Reported balance
After 2018-03-21 transaction · row 1
1 source rowRow 1 · 2018-03-21 · Exercise / conversion · Acquired 1,587 · Balance 3,174 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-03-21 | Direct | 1,586 |
Reported balance
After 2018-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-21 · Exercise / conversion · Disposed 1,587 · Balance 1,586 F1: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board. F2: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board.
F2: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter.
GENERAL ELECTRIC CO
Report date February 22, 2006 · Filed February 24, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,283 |
Reported balance
After 2006-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-02-22 · Grant · Acquired 1,057 · Balance 7,283 F1: 1-for-1 F2: Reallocable to other investment media. Payable after termination of employment. Total includes accrued dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Reallocable to other investment media. Payable after termination of employment. Total includes accrued dividends.
NCR Voyix Corp
Report date September 29, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 951 |
Reported balance
After 2023-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-29 · Grant · Acquired 951 · Balance 951 F1: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2: The phantom stock units are converted into common stock on a one-for-one basis. F3: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program.
F2: The phantom stock units are converted into common stock on a one-for-one basis.
F3: The phantom stock units become payable in common stock following the reporting person's termination of service as a director.
RAYMOND JAMES FINANCIAL INC
Report date February 19, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,285 |
Reported balance
After 2026-02-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 1,303 · Balance 2,285 F1: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors. F2: Includes DRSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors.
F2: Includes DRSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NCR Atleos Corp
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,475 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Exercise / conversion · Acquired 2,690 · Balance 31,475 F1: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program. |
Filing footnotes · ownership attribution and instrument terms
F1: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 27, 2025 Filed Oct 29, 2025 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 174 | $233.88 | $40,694.49 |
DisclosureSEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $233.795 to $234.215, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | GiftCommon Stock | 47 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,893 F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 27,959 | $191.44 | $5,352,470.96 |
DisclosureSEC source: 0001225208-25-008793 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 27,960 | $0.00 Strike: $191.44 | $0.00 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · derivative · entry 13 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,959 Underlying: Common Stock · 27,960 shares Expires 2026-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vested in three equal annual increments beginning 2/21/2021. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 19,841 | $240.95 | $4,780,613.55 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,872 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $240.40 to $241.39, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 17,731 | $241.87 | $4,288,620.02 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,713 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $241.41 to $242.40, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 9,497 | $242.70 | $2,304,935.20 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,444 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $242.41 to $243.17, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 831 | $243.90 | $202,683.56 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,941 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $243.47 to $244.44, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 364 | $244.95 | $89,161.04 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,772 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $244.72 to $245.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:20 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 27,960 | $191.44 | $5,352,662.40 |
DisclosureSEC source: 0001225208-25-006893 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:01 UTC | RAYMOND JAMES FINANCIAL INC RJF · Entity 3126 | GrantCommon Stock | 982 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-005425 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 982 F1 · shares: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors. F2 · balance_after: Includes DRSUs. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:21 UTC | NCR Atleos Corp NATL · Entity 4147 | Exercise / conversionCommon Stock | 2,690 | $25.98 | $69,886.20 |
DisclosureSEC source: 0001415889-25-014469 · form4-05232025_080552.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:21 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 22,160 | $0.00 Strike: $175.48 | $0.00 |
DisclosureSEC source: 0001225208-25-004528 · doc4.xml · derivative · entry 9 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,160 shares Expires 2026-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F3 · derivative.exercise_date: The option vested in three equal annual increments beginning 2/21/2021. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:21 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 22,160 | $256.61 | $5,686,477.60 |
DisclosureSEC source: 0001225208-25-004528 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,395 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 207 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:21 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 22,160 | $175.48 | $3,888,636.80 |
DisclosureSEC source: 0001225208-25-004528 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 207 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:09 UTC | NCR Atleos Corp NATL · Entity 4147 | GrantPhantom Stock Units · Derivative | 996 | $26.38 | $26,274.48 |
DisclosureSEC source: 0001415889-25-009625 · form4-04022025_080407.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,690 Underlying: Common Stock · 996 shares Expires not disclosed F1 · security: These are stocks acquired under the NCR Atleos Director Compensation Program (the "Compensation Program") as part of the reporting persons quarterly cash retainer. The reporting person elected to defer receipt of the quarterly cash retainer as NCR Atleos common stock to be received following the termination of the reporting person's service as a director. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 22,161 | $0.00 Strike: $175.48 | $0.00 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · derivative · entry 13 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,160 Underlying: Common Stock · 22,161 shares Expires 2026-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F9 · derivative.exercise_date: The option vested in three equal annual increments beginning 2/21/2021. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 7,151 | $251.60 | $1,799,157.28 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,243 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F8 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $251.17 to $252.14, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 6,199 | $250.74 | $1,554,326.10 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,394 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $250.095 to $251.03, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 5,214 | $255.27 | $1,330,981.95 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,593 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $254.815 to $255.77, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,600 | $252.38 | $403,804.00 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,807 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $252.24 to $252.61, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,402 | $256.31 | $359,344.24 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,407 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $255.89 to $256.78, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 595 | $253.60 | $150,890.10 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $253.26 to $254.19, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 22,161 | $175.48 | $3,888,812.28 |
DisclosureSEC source: 0001225208-25-001817 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 1,213 | $253.00 | $306,889.00 |
DisclosureSEC source: 0001225208-25-001656 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,243 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:14 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 20,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001656 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,456 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 21,668 | $0.00 Strike: $278.19 | $0.00 |
DisclosureSEC source: 0001225208-25-001576 · doc4.xml · derivative · entry 8 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,668 Underlying: Common Stock · 21,668 shares Expires 2033-02-10 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 23,519 | $0.00 Strike: $303.48 | $0.00 |
DisclosureSEC source: 0001225208-25-001576 · doc4.xml · derivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,519 Underlying: Common Stock · 23,519 shares Expires 2033-02-10 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 13,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001576 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,929 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on February 10, 2028. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 147 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 16:31 UTC | NCR Atleos Corp NATL · Entity 4147 | GrantPhantom Stock Units · Derivative | 774 | $33.92 | $26,254.08 |
DisclosureSEC source: 0001415889-25-000282 · form4-01032025_040114.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,694 Underlying: Common Stock · 774 shares Expires not disclosed F1 · security: These are stocks acquired under the NCR Atleos Director Compensation Program (the "Compensation Program") as part of the reporting persons quarterly cash retainer. The reporting person elected to defer receipt of the quarterly cash retainer as NCR Atleos common stock to be received following the termination of the reporting person's service as a director. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 58,304 | $0.00 Strike: $149.53 | $0.00 |
DisclosureSEC source: 0001225208-24-009538 · doc4.xml · derivative · entry 11 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,304 shares Expires 2025-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 22,254 | $270.45 | $6,018,605.43 |
DisclosureSEC source: 0001225208-24-009538 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,183 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $270.00 to $270.95, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 21,447 | $269.49 | $5,779,700.56 |
DisclosureSEC source: 0001225208-24-009538 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,437 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $269.015 to $269.99, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 7,703 | $272.32 | $2,097,667.86 |
DisclosureSEC source: 0001225208-24-009538 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $272.07 to $272.73, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 6,900 | $271.68 | $1,874,605.80 |
DisclosureSEC source: 0001225208-24-009538 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,587 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $271.085 to $272.06, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 58,304 | $149.53 | $8,718,197.12 |
DisclosureSEC source: 0001225208-24-009538 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:01 UTC | NCR Atleos Corp NATL · Entity 4147 | GrantPhantom Stock Units · Derivative | 920 | $28.53 | $26,247.60 |
DisclosureSEC source: 0001415889-24-024353 · form4-10022024_081051.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 920 Underlying: Common Stock · 920 shares Expires not disclosed F1 · security: These are stocks acquired under the NCR Atleos Director Compensation Program (the "Compensation Program") as part of the reporting persons quarterly cash retainer. The reporting person elected to defer receipt of the quarterly cash retainer as NCR Atleos common stock to be received following the termination of the reporting person's service as a director. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 34,408 | $0.00 Strike: $149.53 | $0.00 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · derivative · entry 14 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,304 Underlying: Common Stock · 34,408 shares Expires 2025-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 23,892 | $0.00 Strike: $138.45 | $0.00 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · derivative · entry 13 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,892 shares Expires 2025-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 22,873 | $270.24 | $6,181,181.22 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $269.81 to $270.78, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 17,594 | $269.38 | $4,739,455.89 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,991 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $268.81 to $269.80, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 7,958 | $268.04 | $2,133,061.52 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,585 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $267.78 to $268.715, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 5,671 | $267.54 | $1,517,241.46 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,543 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $266.765 to $267.7575, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 4,204 | $271.04 | $1,139,440.39 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,214 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $270.79 to $271.415, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 23,892 | $138.45 | $3,307,847.40 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 34,408 | $149.53 | $5,145,028.24 |
DisclosureSEC source: 0001225208-24-007638 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | GiftCommon Stock | 1,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-007563 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,118 Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 21:58 UTC | NCR Atleos Corp NATL · Entity 4147 | GrantPhantom Stock Units · Derivative | 971 | $27.02 | $26,236.42 |
DisclosureSEC source: 0000950170-24-080864 · ownership.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 971 Underlying: Common Stock · 971 shares Expires not disclosed F1 · security: These are stocks acquired under the NCR Atleos Director Compensation Program (the "Compensation Program") as part of the reporting persons quarterly cash retainer. The reporting person elected to defer receipt of the quarterly cash retainer as NCR Atleos common stock to be received following the termination of the reporting person's service as a director. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:49 UTC | NCR Atleos Corp NATL · Entity 4147 | GrantCommon Stock | 5,686 | $28.14 | $160,004.04 |
DisclosureSEC source: 0000950170-24-064085 · ownership.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,445 F1 · shares: These restricted stock units represent the annual equity grant awarded to directors under the NCR Atleos Director Compensation Program (the "Compensation Program"). The restricted stock units vest 12 months after the grant date, subject to the reporting person's continued service as a director on each vesting date. The reporting person elected to defer receipt of NCR Atleos common stock underlying the restricted stock units in accordance with the terms of the Compensation Program. The reporting person will receive NCR Atleos common stock following the termination of the reporting person's service as a director. F2 · balance_after: Includes 2,242 shares from compensation under the NCR Corp Director Compensation Plan, and the reported person elected to defer receipt of common stock until the termination of the reporting person's service as a director. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:16 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 53,003 | $138.45 Strike: $138.45 | $7,338,265.35 |
DisclosureSEC source: 0001225208-24-005392 · doc4.xml · derivative · entry 11 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,892 Underlying: Common Stock · 53,003 shares Expires 2025-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 11/6/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.